The Society
More than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS community
Become an ERS member
The ERS Translational Science Initiative aims to integrate scientific findings from the bench side into the clinic – and vice versa – through a number of ERS-led activities. Here you can find out more about this initiative and related activities.
Translational science can be defined as the process that integrates fundamental respiratory research with clinical science to achieve impact on the quality of life of patients by disease prevention and (personalised) medicine. It is also about then being able to translate results from clinical practice back to the bench side.
A cross-assembly Translational Science Initiative Working Group is facilitating the initiative and integrating it into ERS activity. Each ERS assembly has the chance to contribute.
This initiative prioritises resources to better support translational science, as well as provide a much-needed space for those groups to meet and discuss their issues, address any gaps and get new ideas, ultimately to develop new activities and initiatives.
Anybody with an interest in translational science who would like to play a role in this initiative can do so. The Translational Science Initiative Working Group welcomes contributions from all members who have an interest in basic science, so that they can play a part in the group’s conversations and to see how clinical scientists can be more involved in ERS basic science and research activity.
ERS members should contact their assembly representative, reach out directly to the project lead Prof. Silke Meiners (ERS Conference and Research Seminars Director) or Prof. Irene Heijink (Head of ERS Assembly 3) or email the ERS Scientific Team to discuss ideas in more detail.
Early career members can contribute by contacting the Early Career Members Committee.
The core working group and project leaders for the ERS Translational Science Initiative.
Basic and translational sciences
Basic and translational sciences
ERS members can contribute ideas and suggestions for the Society's Translational Science Initiative by contacting their assembly representative or emailing scientific@ersnet.org.
Respiratory clinical care and physiology
Respiratory intensive care
Sleep disordered breathing
Airway diseases, asthma, COPD and chronic cough
Epidemiology and environment
Paediatrics
Thoracic surgery and transplantation
Allied respiratory professionals
Thoracic oncology
Pulmonary vascular diseases
Clinical techniques, imaging and endoscopy
None
| Company | Purpose of Payment | Amount of funds received* |
|---|---|---|
| AstraZeneca | Ad board, consultancy | B |
| GSK | Ad board, consultancy, steering committee | C |
| Chiesi | Ad board, consultancy, presentation | C |
| Biosency | consultancy | A |
| Menarini | presentation | B |
| Sanofi | ad board | C |
| NOvartis | Ad board | B |
| Zambon | presentation | B |
| Teva | ad board | A |
| Pfizer | ad board | A |
| MSD | presentation | A |
| ALK | presentation | B |
| Company | Purpose and Nature of Benefit | Amount of funds received* |
|---|---|---|
| Chiesi | CPLF | A |
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| GSK | research | D |
| Pfizer | research | D |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
None
None
None
None
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
| Company | Area | Product | Amount of funds received* |
|---|---|---|---|
| AZ | airways disease | N/A | B |
| GSK | airways disease | N/A | C |
| Chiesi | Airways Disease | N/A | C |
| Areteia | Airways Disease | N/A | B |
None
None
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| Research Grants | AZ | D |
| Company or organisation | Nature/Purpose of Support |
|---|---|
| Eupnoos Limited | Chief Scientific Officer, Co-founder and 5% equity holder |
| Astra Zeneca | Part of an AZ funded remission steering group in asthma. |
| Astra Zeneca | Part of an AZ coordinated group developing asthma remission consensus statement |
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |